The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Current Status of Gadolinium Toxicity in Patients with Kidney Disease
Abstract
Gadolinium-based contrast (GBC) agents have recently been the subject of intense interest for physicians across numerous specialties. These agents are widely used as contrast for magnetic resonance imaging and have been generally considered safe. Early on, phase III trials and small studies in low-risk patients suggested a benign renal profile; however, more recent studies raised the possibility of nephrotoxicity, although it is not clear whether it approaches the incidence of nephropathy associated with iodinated radiocontrast. In 2006, reports of a rare systemic fibrosing condition called nephrogenic systemic fibrosis (NSF) were recently linked to exposure of patients with advanced kidney disease to GBC agents. Analysis of the data suggests that certain GBC agents are more likely to be associated with NSF. Also, not all patients with kidney disease are at risk for developing NSF, only those with advanced acute or chronic kidney disease. Avoidance of GBC exposure is the best approach for high-risk patients. When GBC is required to obtain optimal images, use of low dosages of more stable macrocyclic agents is safer and preferred. This article reviews the current status of GBC agents as nephrotoxins and causes of NSF and provides opinions on how to use these agents in patients with underlying kidney disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ever more evidence is accumulating that gadolinium-based contrast enhancement agents induce nephrogenic systemic fibrosis (NSF) in patients with underlying kidney disease. As a consequence, gadolinium-based contrast agents are contraindicated in patients with impaired renal function [187].”
From Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications (2019) · cites this paper as [187]
Citations
Cites
Grobner, T. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfk062 · Cited by 1,862
Marckmann, P., Skov, L., Rossen, K., Dupont, A., Damholt, M. B., Heaf, J. G., & Thomsen, H. S. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006060601 · Cited by 1,398
Nephrogenic Systemic Fibrosis: Risk Factors and Incidence Estimation
Sadowski, E. A., Bennett, L. K., Chan, M. R., Wentland, A. L., Garrett, A. L., Garrett, R. W., & Djamali, A. (2007) · Radiology · doi:10.1148/radiol.2431062144 · Cited by 1,011
Gadodiamide-Associated Nephrogenic Systemic Fibrosis: Why Radiologists Should Be Concerned
Broome, D. R., Girguis, M. S., Baron, P. W., Cottrell, A. C., Kjellin, I. B., & Kirk, G. A. (2007) · American Journal of Roentgenology · doi:10.2214/ajr.06.1094 · Cited by 599
Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis
High, W. A., Ayers, R. A., Chandler, J. P., Zito, G., & Cowper, S. E. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.10.047 · Cited by 542
Nephrogenic Fibrosing Dermopathy
Cowper, S. E., Su, L. D., Bhawan, J., Robin, H. S., & LeBoit, P. E. (2001) · American Journal of Dermatopathology · doi:10.1097/00000372-200110000-00001 · Cited by 473
Nephrotoxicity of high‐dose gadolinium compared with iodinated contrast
Prince, M. R., Arnoldus, C. L., & Frisoli, J. K. (1996) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.1880060129 · Cited by 401
Gadolinium deposition in nephrogenic fibrosing dermopathy
Boyd, A. S., Zic, J. A., & Abraham, J. L. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.10.048 · Cited by 374
Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide
Thomsen, H. S. (2006) · European Radiology · doi:10.1007/s00330-006-0495-8 · Cited by 352
Collidge, T., Thomson, P. C., Mark, P. B., Traynor, J. P., Jardine, A. G., Morris, S., Simpson, K., & Roditi, G. (2007) · Radiology · doi:10.1148/radiol.2451070353 · Cited by 319
Cited by
Sorted by citations
Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications
Dadfar, S. M., Roemhild, K., Drude, N. I., von Stillfried, S., Knüchel, R., Kiessling, F., & Lammers, T. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.01.005 · Cited by 1,181
X-ray-Computed Tomography Contrast Agents
Lusic, H., & Grinstaff, M. W. (2012) · Chemical Reviews · doi:10.1021/cr200358s · Cited by 1,150
Nanomaterials for In Vivo Imaging
Smith, B. R., & Gambhir, S. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00073 · Cited by 1,084
ACCF/ACR/AHA/NASCI/SCMR 2010 Expert Consensus Document on Cardiovascular Magnetic Resonance
Hundley, W. G., Bluemke, D. A., Finn, J. P., Flamm, S. D., Fogel, M. A., Friedrich, M. G., Ho, V. B., Jerosch‐Herold, M., Kramer, C. M., Manning, W. J., et al. (2010) · Circulation · doi:10.1161/cir.0b013e3181d44a8f · Cited by 822
Upconverting nanoparticles: assessing the toxicity
Gnach, A., Lipiński, T., Bednarkiewicz, A., Rybka, J., & Capobianco, J. A. (2014) · Chemical Society Reviews · doi:10.1039/c4cs00177j · Cited by 663
Metadata
- Authors
- Perazella, M. A.
- Affiliations
- Yale University (US)
- Corresponding author
- Perazella, Mark A.
- ORCID
- Perazella, Mark A.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2009-02
- Volume
- 4
- Issue
- 2
- Pages
- 461-469
- ISSN
- 1555-9041 (ISSN-L)
- OpenAlex
- W2116878814
- Cited by
- 275
- References
- 42
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 8 · 2023: 7 · 2022: 17 · 2021: 16 · 2020: 7 · 2019: 21 · 2018: 22 · 2017: 23 · 2016: 12 · 2015: 18 · 2014: 15 · 2013: 17 · 2012: 29
- FWCI
- 12.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Journal of the American Society of Nephrology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Society of Nephrology
- Topics
- Physical Sciences › Materials Science › Materials Chemistry › Lanthanide and Transition Metal Complexes
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- gadolinium-based contrast agents, nephrogenic systemic fibrosis, nephrotoxicity, chronic kidney disease, acute kidney injury, MRI contrast safety
- MeSH terms
- Animals, Contrast Media, Dose-Response Relationship, Drug, Gadolinium, Humans, Kidney Diseases, Magnetic Resonance Imaging, Risk Factors, Risk Assessment, Evidence-Based Medicine, Nephrogenic Fibrosing Dermopathy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
